{"id":"open-label-semuloparin-sodium","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2108718","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Semuloparin is a low-molecular-weight heparin (LMWH) derivative that selectively inhibits Factor Xa, a key enzyme in the coagulation cascade. By blocking Factor Xa activity, it prevents the conversion of prothrombin to thrombin, thereby reducing thrombus formation. It is used for thromboprophylaxis in patients at high risk of venous thromboembolism.","oneSentence":"Semuloparin sodium is a selective inhibitor of Factor Xa that prevents thrombin generation and blood clot formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:32.596Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis in patients undergoing abdominal surgery"},{"name":"Thromboprophylaxis in patients with acute medical illness"}]},"trialDetails":[{"nctId":"NCT01567904","phase":"PHASE2","title":"Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line","status":"TERMINATED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)","enrollment":2},{"nctId":"NCT00709904","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Venous Thromboembolism","enrollment":469}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AVE5026"],"phase":"phase_3","status":"active","brandName":"Open-label Semuloparin sodium","genericName":"Open-label Semuloparin sodium","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semuloparin sodium is a selective inhibitor of Factor Xa that prevents thrombin generation and blood clot formation. Used for Thromboprophylaxis in patients undergoing abdominal surgery, Thromboprophylaxis in patients with acute medical illness.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}